OPTIMISE2:老年轻度高血压高危患者减停降压药的非劣效性试验方案
OPTIMISE2 计划纳入 3014 例 75 岁及以上、服用两种及以上降压药且血压已控制、伴衰弱或低血压/晕厥/跌倒高风险的患者,1:1 随机分为逐步减药组与常规照护组,随访 1 年;主要结局为随机化后 1 年内急诊住院或死亡,以 5% 差异界值判定减药非劣效,并评估成本效果。
要点
- 对 75 岁以上血压已控制且不良事件高风险的老年患者,逐步减停降压药需在监测下进行。
- 主要结局为 1 年内急诊住院或死亡,非劣效界值为 5% 的差异。
- 研究同时开展经济学评价,为指南与基层实践提供减药证据。
核心结论
- 旨在检验对血压已控制的老年高危患者减停降压治疗是否在急诊住院或死亡方面非劣于常规照护。
研究设计与样本
- 基层开放标签随机对照非劣效性试验,计划纳入 3014 例,1:1 随机,主动随访 1 年。
- 入选条件为 75 岁及以上、服用两种及以上降压药、血压控制(75-79 岁收缩压<140 mmHg,80 岁及以上<150 mmHg)、衰弱和/或低血压、晕厥、跌倒等药物相关严重不良反应高风险。
主要发现
- 原文未报告结果,仅报告试验设计与主要结局定义。
关键数值与推荐
- 主要结局为随机化后 1 年内急诊住院或死亡。
- 非劣效界值为两组发生急诊住院/死亡的患者百分比差异不超过 5%。
- 减药组每次撤停一种降压药,间隔 4 周并定期监测血压;常规照护组不强制减药,具体撤停药物由全科医生或处方者决定。
临床怎么用
- 结果预期用于指导老年衰弱、血压已控制但不良事件高风险患者的降压药减停临床指南与实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antihypertensive treatment is effective at reducing the risk of cardiovascular disease, but is associated with adverse events, particularly in older patients with frailty. As a result, deprescribing antihypertensive medications is recommended in some clinical guidelines despite limited evidence from a few small randomised controlled trials. The aim of the OPTIMISE2 trial is to examine the safety, efficacy and cost-effectiveness of deprescribing antihypertensive treatment in older adults with controlled systolic blood pressure, who are at higher risk of adverse events. METHODS: The OPTIMISE2 trial aims to enrol 3014 participants into the trial and actively follow them up for 1 year. Participants are aged 75 years and above and taking two or more blood pressure lowering drugs, with controlled blood pressure readings (systolic blood pressure < 140 mmHg if aged 75-79 years or < 150 mmHg if aged 80+ years), frail and/or at a higher risk of serious drug-related side effects of hypotension, syncope and falls. The trial randomises (1:1) participants to either step-down medication reduction (withdrawal of one antihypertensive medication at a time, at 4-week intervals with regular monitoring of blood pressure) or usual care (no medication reduction mandated). The choice of medications to withdraw is at the discretion of participating general practitioners or prescribers. The primary outcome is emergency hospitalisation or death within 1 year of randomisation. The primary objective is to determine whether antihypertensive deprescribing is non-inferior to usual care, with up to a 5% difference in the percentage of patients with an emergency hospitalisation/death. The study uses a within-trial economic evaluation and decision-analytic modelling to estimate the cost-effectiveness of deprescribing antihypertensive treatment. DISCUSSION: It is expected that these findings will inform clinical guidelines and practice about deprescribing of antihypertensive medications in older adults with frailty, who have controlled systolic blood pressure but are at higher risk of adverse events. TRIAL REGISTRATION: ISRCTN18030225. Registered on 19/09/2023. Secondary Identifying Numbers: University of Oxford Sponsor Protocol Number 16667. IRAS 1006598. CPMS 56390.
引用
- Carr M, Kenealy N, Yu LM, et al. Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trial. Trials. 2026. PMID: 41689048. doi:10.1186/s13063-026-09508-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。